Intended for healthcare professionals


Intrapleural streptokinase for pleural infection

BMJ 2006; 332 doi: (Published 02 March 2006) Cite this as: BMJ 2006;332:552
  1. Nick Maskell, consultant chest physician (,
  2. Andrew Nunn, associate director,
  3. Robert J O Davies, reader in respiratory medicine
  1. Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB
  2. MRC Clinical Trials Unit, London NW1 2DA
  3. Oxford Centre for Respiratory Medicine, Oxford Radcliffe Hospital, Oxford OX3 7LJ

    EDITOR—In their editorial on intrapleural streptokinase for pleural infection Bouros and Light raise several points about the results of the MIST1 trial.1 2

    They say that a treatment effect may have been overlooked since MIST1 enrolled a representative population of patients with pleural infection, including those with late “organised” disease. The analysis in the primary publication describing our trial result shows that this is not true.2 In the …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription